



1

2

3

4

5 CADTH Reimbursement Recommendation

6

7

8

9

10

11 | Streamlined Drug Class Review

12 **DRAFT for Stakeholder Feedback**

13

# **Sodium-Glucose Cotransporter 2 Inhibitors in Type 2 Diabetes Mellitus**

14

November 30, 2023

15

# Summary of CADTH FMEC

16

## Recommendation

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

### Recommendation 1

39

40

41

42

43

44

45

46

47

48

49

### Recommendation 2

- SGLT2 inhibitors should be prioritized over GLP-1 agonists in adult patients diagnosed with type 2 diabetes mellitus following inadequate control with metformin or a contraindication/intolerance to metformin unless the drug plan cost per patient of a GLP-1 agonist is no more than the least costly SGLT2 inhibitor.

## 50 Therapeutic Landscape

### 51 What Is Type 2 Diabetes Mellitus?

52 Diabetes mellitus is a heterogeneous metabolic disorder characterized by the  
53 presence of hyperglycemia due to impairment of insulin secretion, defective  
54 insulin action, or both. Type 2 diabetes mellitus is caused by insulin  
55 resistance related to insulin deficiency or secretory defect. Type 2 diabetes  
56 mellitus is associated with high mortality and complications which include  
57 myocardial infarction, stroke, end-stage renal disease, as well as  
58 microvascular complications such as retinopathy and nephropathy.

### 59 Why Did CADTH Conduct This Review?

60 Publicly funded drug plans requested this Streamlined Drug Class Review of  
61 SGLT2 inhibitors given the emergence of new evidence in cardiorenal  
62 benefits and the loss of exclusivity of drugs within the class.

63

64

#### **Persons with Lived Experience**

65 Two people living with type 2 diabetes spoke directly to the committee on their  
66 experiences and distinctive challenges living with the condition and with  
67 SGLT2s and GLP-1 treatments. One person highlighted different obstacles  
68 affecting their employment as a truck driver, including the frequent need to  
69 check blood sugar levels, managing side effects, and the inconvenience of  
subcutaneous injections. The other person highlighted minimal side effects  
from their treatments but underscored the supply chain issues of GLP-1s as  
having a profound impact.

70 Both individuals expressed concerns for the financial strain of medications.  
71 People living in rural areas may have additional costs and challenges to access  
72 specialist care and resources. They also stressed the significance of the impact  
of diet and flexibility of treatment options on their quality of life.

73 Living long enough to watch their children grow up was a primary factor when  
discussing treatment options.

## 74 Stakeholder Feedback

### 75 What Did We Hear From Patients?

76 CADTH consulted with Diabetes Canada throughout the project. CADTH also  
77 considered insights from the [Living with Type 2 Diabetes](#) collaborative review.  
78 Patients living with type 2 diabetes want less invasive treatment options to reduce  
79 the burden of medication administration. There is a desire to increase access to and  
80 affordability of treatments. People living with type 2 diabetes also want medications  
81 with few or no adverse effects, especially hypoglycemia, weight gain, and  
82 gastrointestinal and urogenital side effects.

### 83 What Did We Hear From Clinicians?

84 CADTH did not receive input from clinician groups during the open call for  
85 stakeholder feedback. Clinical experts consulted by CADTH noted the importance of  
86 aligning this review with Diabetes Canada's Clinical Practice Guidelines.

### 87 What Did We Hear From the Pharmaceutical Industry?

88 CADTH received input from two manufacturers on the project scope and feedback  
89 from three manufacturers on the summary report. Questions were posed related to  
90 the procedures and alignment of study objectives and research questions. One  
91 manufacturer raised concerns with the lack of discussion about combination use of  
92 GLP-1 agonist and insulin. Another manufacturer disagreed with the assumption of  
93 no intraclass differences within the GLP-1 agonist drug class, citing an unblinded  
94 phase IV study. Some manufacturers suggested incorporating additional studies.  
95 One manufacturer suggested that the CADTH review should align with the Diabetes  
96 Canada Clinical Practice Guidelines.

### 97 What Did We Hear From Public Drug Programs?

98 Feedback from public drug programs included the request for additional  
99 comparators (i.e., basal insulins) and outcomes (e.g., change in HbA1c) to support  
100 decision making.

101

Refer to [Stakeholder Input](#) section of the CADTH report

## Deliberative Summary

### Table 1: Why Did FMEC Make This Recommendation?

Questions or considerations	Discussion Points
<p><b>Is there sufficient evidence to support the added clinical benefit of SGLT2 inhibitors compared to GLP-1 agonists, sulfonylureas, DPP-4 inhibitors, and basal insulins?</b></p>	<p>FMEC noted the importance to evaluate clinically relevant outcomes such as all-cause death and cardiorenal benefits (e.g., reduction in cardiovascular events or end-stage renal disease). Surrogate outcomes (e.g., change in HbA1C or body weight) for the treatment of type 2 diabetes mellitus were also considered by FMEC.</p> <p><b>SGLT2 inhibitors vs. GLP-1 agonists</b></p> <ul style="list-style-type: none"> <li>SGLT2 inhibitors and GLP-1 agonists have comparable efficacy based on all-cause death, cardiovascular benefits, and HRQoL. In addition, SGLT2 inhibitors are more favourable in the reduction of hospitalization related to heart failure and the reduction in end-stage renal disease. However, GLP-1 agonists are more favourable in the reduction of non-fatal stroke.</li> <li>SGLT2 inhibitors are associated with mycotic infections (OR 3.30, 95% CI 2.88 to 3.78), amputation (OR 1.27, 95% CI 1.01 to 1.61), and ketoacidosis (OR 2.07, 95% CI 1.44 to 2.98); whereas GLP-1 agonists are associated with severe gastrointestinal events (OR 1.97, 95% CI 1.39 to 2.80).</li> <li>FMEC deliberated on the evidence and agreed that SGLT2 inhibitors and GLP-1 agonists are overall comparable in mortality and important cardiorenal benefits. FMEC also acknowledged the difference in stroke reduction for GLP-1 agonists, with a detailed review of absolute difference in event rates. Given SGLT2 inhibitors also benefit in the reduction of heart failure related hospitalization and end-stage renal disease, FMEC concluded these differences were marginal.</li> <li>Dissenting opinion noted the GLP-1 agonists offer improved change in body weight and HbA1C compared to SGLT2 inhibitors. Additionally, it was noted that type 2 diabetes mellitus is a heterogeneous condition that requires individualization of therapy according to a</li> </ul>

Questions or considerations	Discussion Points
	<p>patient's clinical characteristics, risk profile, and/or personal preference.</p> <p><b>SGLT2 inhibitors vs. Sulfonylureas</b></p> <ul style="list-style-type: none"> <li>SGLT2 inhibitors offer benefits in all-cause death and cardiorenal benefits, whereas sulfonylureas have not demonstrated these benefits.</li> <li>Sulfonylureas are associated with a higher risk of severe hypoglycemia and weight gain.</li> </ul> <p><b>SGLT2 inhibitors vs. DPP-4 Inhibitors</b></p> <ul style="list-style-type: none"> <li>SGLT2 inhibitors offer benefits in all-cause death and cardiorenal benefits, whereas DPP-4 inhibitors have not demonstrated these benefits.</li> </ul> <p><b>SGLT2 inhibitors vs. Basal Insulins</b></p> <ul style="list-style-type: none"> <li>SGLT2 inhibitors offer benefits in all-cause death and cardiorenal benefits, whereas basal insulins have not demonstrated these benefits.</li> <li>Basal insulins are associated with higher risk of severe hypoglycemia and weight gain.</li> <li>FMEC discussed that exogenous insulin plays a different role in the management of type 2 diabetes mellitus compared to oral antihyperglycemics and may always be a treatment option over the course of the disease.</li> </ul>
<p><b>Is there a high level of confidence in the NMA to support differences between SGLT2 inhibitors and GLP-1 agonists, sulfonylureas, DPP-4 inhibitors, and basal insulins?</b></p>	<ul style="list-style-type: none"> <li>FMEC noted that the NMA selected for the class review was of rigorous methodology. All outcomes have been rated for the certainty of evidence following the GRADE approach and the review followed the established protocol described in the publication.</li> <li>Both SGLT2 inhibitors and GLP-1 agonists are more favourable than standard treatments for the following outcomes (rated with high to moderate certainty): all-cause death, cardiovascular death, non-fatal myocardial infarction, and HRQoL. Note that standard treatments include standard care (e.g., lifestyle modification) and standard drug treatments (e.g., metformin and/or sulfonylureas) other than the drug under investigation.</li> </ul>
<p><b>Is there an economic benefit of prioritizing SGLT2 inhibitors</b></p>	<ul style="list-style-type: none"> <li>FMEC noted that the annual costs of branded SGLT2 inhibitors are approximately four times higher than the</li> </ul>

Questions or considerations	Discussion Points
compared to GLP-1 agonists, sulfonylureas, DPP-4 inhibitors, and basal insulins?	<p>generic SGLT2 inhibitors. Dapagliflozin has generic versions currently available; several generic versions for canagliflozin and empagliflozin are currently under review by Health Canada.</p> <ul style="list-style-type: none"> <li>FMEC noted the annual cost of a generic version of dapagliflozin is approximately 10 times lower than the annual cost of semaglutide at list prices. The annual costs of branded SGLT2 inhibitors are less than the annual costs of all GLP-1 agonists.</li> <li>The annual costs of generic SGLT2 inhibitors are less than the annual costs of branded DPP-4 inhibitors. The annual costs of generic SGLT2 inhibitors are comparable or less than the generic DPP-4 inhibitors.</li> <li>The annual costs of generic SGLT2 inhibitors are higher than the annual costs of sulfonylureas.</li> <li>The annual costs of basal insulins cannot be determined given the variability of insulin doses and types.</li> </ul>
Is there an intraclass difference to be considered?	<ul style="list-style-type: none"> <li>FMEC agreed with the NMA authors that there should be no significant intraclass differences among the drugs under review (i.e., SGLT2 inhibitors, GLP-1 agonists, DPP-4 inhibitors, and sulfonylureas).</li> <li>FMEC discussed a potential for intraclass differences amongst SGLT2 inhibitors. There was dissenting opinion that CDEC concluded that ertugliflozin has not demonstrated survival or cardiovascular benefit, however, ertugliflozin is not available in Canada.</li> <li>FMEC also discussed the stakeholder feedback on potential intraclass differences among the GLP-1 agonists and highlighted the NMA included several GLP-1 agonists that are not available in Canada. Two re-analyses were conducted including semaglutide and dulaglutide together and semaglutide alone. Both re-analyses revealed consistent findings compared to the original NMA results. These findings suggest there is a lack of intraclass variability.</li> </ul>

SU: sulfonylureas; SGLT2 = sodium-glucose cotransporter-2; GLP-1 = glucagon like peptide; DPP-4 = dipeptidyl peptidase-4; HRQoL = health related quality of life

105  
106

107

## Decision Plane

A decision plane was used during the deliberation to assess the classes of SGLT2 inhibitors within two domains: cost and favourability (as defined by the totality of evidence on efficacy and safety). With SGLT2 inhibitors at the origin, FMEC deliberated on the relative location of sulfonylureas, dipeptidyl peptidase-4 (DPP-4) inhibitors, GLP-1 agonists, and basal insulins on the decision plane.


FMEC concluded that GLP-1 agonists and SGLT2 inhibitors have similar efficacy in outcomes deemed most important by FMEC, recognizing they both offer marginal benefits in different aspects. GLP-1 agonists were also more costly.

Sulfonylureas were less favourable compared to SGLT2 inhibitors, despite having lower costs. DPP-4 inhibitors were less favourable compared to SGLT2 inhibitors. DPP-4 inhibitors cost more or less per patient than SGLT2 inhibitors, which differs based on version (branded vs generic).

Given the role basal insulins play in the management of type 2 diabetes and the uncertainty in cost associated with its use, the committee was unable to determine the location of basal insulins on the decision plane.

**Figure 1:**  
**Decision Plane**

Drug classes are represented by squares plotted on the decision plane. The area of the squares aims to illustrate potential variability for cost and clinical favourability within the class. Squares crossing over the horizontal or vertical axes demonstrate variability in cost and clinical favourability in comparison to the drug class at the origin.







## Feedback on Draft Recommendation

<to be updated after the stakeholder feedback period>

## FMEC Information

**Members of the Committee:** Dr. Emily Reynen (Chair), Dr. Alun Edwards, Ms. Valerie McDonald, Dr. Jim Silvius, Dr. Marianne Taylor, Dr. Maureen Trudeau, Dr. Dominika Wranik, Dr. Zaina Albalawi (guest specialist), Dr. Parmjit Sohal (guest specialist)

**Meeting date:** November 30, 2023

**Conflicts of interest:** None

**Special thanks:** CADTH extends our special thanks to the individuals who presented directly to FMEC on behalf of patients with lived experience, patient organizations representing the community of those living with type 2 diabetes mellitus, Diabetes Canada and Diabetes Action Canada, which included Laura Hoffe, Vikramjit Brar, Linxi Mytkoll, Al Martin, and Barb Duff.

The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.

While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.

CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.

This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners' own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.

Subject to the aforementioned limitations, the views expressed herein are those of CADTH and do not necessarily represent the views of Canada's federal, provincial, or territorial governments or any third-party supplier of information.

This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user's own risk.

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

Confidential information in this document may be redacted at the request of the sponsor in accordance with the CADTH Drug Reimbursement Review Confidentiality Guidelines. CADTH was established by Canada's federal, provincial, and territorial governments to be a trusted source of independent information and advice for the country's publicly funded health care systems. Health administrators and policy experts rely on CADTH to help inform their decisions about the life cycle management of drugs, devices, and services used to prevent, diagnose, and treat medical conditions.

CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec.

**cadth.ca**

January 2024